Protalix BioTherapeutics Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Protalix BioTherapeutics, Inc. (PLX) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Operating Activities
Net Income2.938.31-14.93-27.58-6.52-18.28-26.46
Depreciation & Amortization1.301.191.401.121.304.591.67
Deferred Income Tax0.24-3.090.000.000.000.000.00
Stock Based Compensation3.253.452.092.383.130.000.00
Change in Working Capital0.81-10.54-12.019.90-27.13-6.7313.51
Change in Accounts Receivable2.32-0.43-1.19-1.032.090.000.00
Change in Inventory-2.20-2.241.15-4.87-4.930.000.00
Change in Accounts Payable0.005.30-4.802.392.270.000.00
Change in Other Working Capital0.690.010.000.19-0.360.000.00
Other Operating Activities0.14-4.012.081.28-0.350.673.07
Net Cash from Operating Activities8.67-1.32-25.00-10.29-26.11-19.36-7.74
Investing Activities
Capital Expenditures-1.28-1.150.63-1.46-0.660.63-0.69
Purchases of Investments-15.00-15.42-5.0020.00-20.000.000.00
Sales/Maturities of Investments20.425.00-4.4157.84-19.30-0.260.00
Other Investing Activities0.08-0.14-4.410.330.70-0.260.10
Net Cash from Investing Activities4.22-16.71-5.0418.92-19.95-0.88-0.59
Financing Activities
Debt Repayment-20.420.000.00-34.12-0.220.00-4.75
Common Stock Issued3.6324.678.2446.2046.680.000.00
Net Cash from Financing Activities-16.7924.678.2412.0846.470.00-4.75
Summary
Effect of Forex Changes on Cash0.03-0.11-0.080.010.060.23-0.27
Net Change in Cash-3.876.52-21.8020.720.47-20.02-13.09
Cash at Beginning of Period23.6317.1138.9918.2717.7937.8151.16
Cash at End of Period19.7623.6317.1138.9918.2737.8137.81
Free Cash Flow7.39-2.47-25.63-11.74-26.76-19.99-8.43
Supplemental Disclosures
Interest Paid1.532.742.203.414.344.344.59
Income Taxes Paid0.390.000.000.000.000.000.00